Table 1.

The list of ICIs with the cancer type indication.

Drug	Target	Approval	FDA-Approved Indications	References
Nivolumab	PD-1	March 2015	Stage III-B or IV Squamous NSCLC	[19]
Pembrolizumab	PD-1	October 2016	Stage IV nonsquamous and squamous NSCLC	[20]
Atezolizumab	PD-L1	October 2016	Stage III-B or IV nonsquamous and squamous NSCLC	[21]
Cemiplimab	PD-1	September 2018	metastatic cutaneous squamous cell carcinoma	[22]
Ipilimumab	CTLA-4	August 2010	stage 3 or 4 malignant melanoma	[23]
Avelumab	PD-L1	March 2017	histologically confirmed metastatic Merkel cell carcinoma	[24]
Durvalumab	PD-L1	February 2016	Stage III non-small-cell lung cancer (NSCLC)	[25]
Pembrolizumab + cis/carboplatin + pemetrexed	-	August 2018	Nonsquamous NSCLC	[26]
Pembrolizumab + paclitaxel/nab-paclitaxel + carboplatin	-	October 2018	Stage IV Squamous NSCLC	[27]
Atezolizumab + carboplatin + paclitaxel + bevacizumab	-	December 2018	Stage IV NSCLC	[28]